Curated News
By: NewsRamp Editorial Staff
October 15, 2026
OrthodontiCell Secures Funding for Phase II Pivotal Study of Bioelectric Tooth Movement Tech
TLDR
- OrthodontiCell secured capital to complete testing for a Phase II pivotal study, advancing its bioelectric tooth movement technology ahead of rivals.
- OrthodontiCell will use new capital to finish testing, then submit for regulatory approval to start a Phase II pivotal study on bioelectric tooth movement.
- OrthodontiCell's bioelectric technology could shorten orthodontic treatment, offering patients a faster path to a healthy, confident smile.
- OrthodontiCell's bioelectric technology uses controlled stimulation to accelerate tooth movement, potentially reducing time in braces.
Impact - Why it Matters
This news matters because it brings the dental and orthodontic field one step closer to a potentially transformative treatment option. If successful, bioelectric technology could significantly reduce the duration of orthodontic treatment, which typically takes two years or more. Shorter treatment times would not only improve patient convenience and satisfaction but also could lead to better oral health outcomes due to improved compliance. For the estimated 4 million Americans who undergo orthodontic treatment annually, this technology could mean less time in braces or aligners, fewer office visits, and a faster path to a confident smile. Moreover, it represents a novel application of bioelectric stimulation in dentistry, opening doors for further innovations in regenerative and accelerated healing therapies. The funding milestone signals growing investor confidence in OrthodontiCell's approach and underscores the potential for non-invasive, drug-free solutions to common orthodontic challenges. As the company moves toward regulatory submission, the successful completion of this study could pave the way for a new standard of care in orthodontics.
Summary
OrthodontiCell, Inc. has secured sufficient capital to complete the remaining testing required for its application to launch a planned Phase II pivotal clinical study in the United States. This funding milestone supports the company's development of bioelectric technology aimed at accelerating tooth movement during orthodontic treatment, potentially shortening treatment time and enhancing patient experience. The capital allows OrthodontiCell to finalize testing and prepare its regulatory submission to initiate the final pivotal U.S. study, which will evaluate the technology's safety and effectiveness, including its potential to reduce the time needed to straighten teeth. Details on study design, participating centers, and enrollment timing will be announced as the program advances.
Mark Terrill, CEO of OrthodontiCell, remarked, “For patients and families, a shorter path to a healthy, confident smile can make a meaningful difference. Securing the capital to complete this testing moves OrthodontiCell closer to its next clinical milestone and gives our team the resources to advance the application process.” The secured funds specifically cover the remaining testing for the application, while funding for conducting the pivotal study itself will be addressed separately. OrthodontiCell is focused on developing bioelectric technology to accelerate orthodontic tooth movement and improve treatment experiences, with its program evaluating controlled bioelectric stimulation alongside orthodontic care. The technology remains investigational, and the planned study's initiation depends on testing completion and regulatory and ethics approvals. Forward-looking statements about development plans and treatment benefits reflect current expectations, but actual results and timing may vary.
Source Statement
This curated news summary relied on content distributed by Newsworthy.ai. Read the original source here, OrthodontiCell Secures Funding for Phase II Pivotal Study of Bioelectric Tooth Movement Tech
